* Xeris Biopharma Holdings Inc XERS.OQ reported a
quarterly
adjusted loss of 10 cents per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of -14 cents. The mean expectation of six analysts
for the quarter was for a loss of 11 cents per share. Wall
Street expected results to range from -12 cents to -9 cents per
share.
* Revenue rose 26.5% to $48.07 million from a year ago;
analysts
expected $45.81 million.
* Xeris Biopharma Holdings Inc's reported EPS for the
quarter was
a loss of 10 cents.
* The company reported a quarterly loss of $15.01 million.
* Xeris Biopharma Holdings Inc shares had fallen by 5.3%
this
quarter and lost 9.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 3% in
the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is "buy."
Wall Street's median 12-month price target for Xeris Biopharma
Holdings Inc is $4.75
This summary was machine generated from LSEG data August 8 at
02:21 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.11 -0.10 Beat
Mar. 31 2024 -0.12 -0.14 Missed
Dec. 31 2023 -0.10 -0.10 Met
Sep. 30 2023 -0.12 -0.09 Beat